• Outlook Therapeutics received a Nasdaq notice for failing the $1.00 minimum bid price rule, following 30 straight business days below $1.00.
• Shares remain listed on the Nasdaq Capital Market while the company has until March 24, 2027 to regain compliance.
• Compliance requires a closing bid price of at least $1.00 for 10 consecutive business days before the deadline.
• Failure to cure could trigger a delisting determination, with a possible appeal to a Nasdaq hearings panel.
• An additional 180-day cure period may be available, including via a reverse stock split, subject to eligibility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-112356), on September 30, 2026, and is solely responsible for the information contained therein.